Boosting Liver Health with Gut Microbes: Probiotics Enhance CD4+ T Cell Immunity Against Hepatitis B

Gut Microbiome and Probiotics in T Cell Immunity

The gut microbiome and probiotics significantly influence T cell immunity in several important ways:

1. Promote Regulatory T Cells (Tregs): Certain bacteria and their metabolites, like short-chain fatty acids, induce Tregs, which are crucial for maintaining immune tolerance and regulating inflammatory responses. For example, Clostridium species have been shown to promote Treg cell accumulation and function in the colon [2, 3, 4].
2. Enhance T Helper 1 (Th1) Cells: Specific commensal bacteria can stimulate Th1 differentiation, boosting immunity against intracellular pathogens. For instance, Bacteroides fragilis has been found to promote Th1-associated immune responses through its bacterial product polysaccharide A [3].
3. Regulate T Helper 17 (Th17) Cells: Probiotics can modulate Th17 responses, helping to balance pathogen defense and inflammation control. Segmented filamentous bacteria (SFB) have been shown to induce Th17 cell differentiation in the small intestine [3].
4. Reduce T Helper 2 (Th2) Cells: Probiotics can help mitigate allergic responses by balancing Th1/Th2 responses. Some probiotic strains have been found to suppress Th2-mediated allergic reactions.
5. Modulate Cytokine Production: Probiotics influence both anti-inflammatory and pro-inflammatory cytokine production. For example, certain probiotic strains can increase the production of anti-inflammatory cytokines like IL-10 [3].
6. Support Gut Barrier Integrity: A healthy microbiota helps maintain gut barrier function, preventing unnecessary T cell activation. Probiotics can enhance the production of mucus and antimicrobial peptides by intestinal epithelial cells.
7. Affect Systemic Immunity: Microbiome imbalances can contribute to autoimmune conditions and chronic inflammation. Studies have shown that alterations in the gut microbiota composition are associated with various autoimmune diseases.

These interactions highlight the potential of microbiome-targeted therapies for immune-related disorders. The ability of probiotics to modulate T cell responses and maintain immune homeostasis makes them promising candidates for treating conditions characterized by immune dysregulation.

Mechanism of Action: Probiotics and CD4+ T Cells

The study by Wang et al. demonstrates that specific probiotics, referred to as BLE (comprising Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis), can enhance the immune response to HBV through two primary mechanisms. Firstly, these probiotics help establish intestinal homeostasis and improve the gut barrier, essential for systemic immune health. BLE administration was found to enrich specific beneficial bacterial families in the gut, which in turn supported immune resilience by regulating intestinal barrier integrity and immune responses. This effect is particularly notable in maintaining a balance of Th1, Th17, and regulatory T cell (Treg) populations, each playing distinct roles in immune regulation and pathogen defense. BLE specifically increased IL-17A, IL-21, and IL-22 expressions to support gut integrity and immune function.

Secondly, and perhaps more crucially, BLE’s metabolite spermidine (SPD) plays an essential role in the liver’s immune response to HBV. The study found that SPD directly enhances CD4+ T cell activity by increasing autophagy—a process where cells recycle their components, crucial for immune cell function. Through autophagy, spermidine boosts the production of interferon-gamma (IFN-γ) by CD4+ T cells, a cytokine pivotal in antiviral responses. SPD also increased IL-21, a cytokine involved in antiviral responses.

Spermidine’s Influence on CD4+ T Cells and Autophagy

Spermidine produced by BLE probiotics exerts a powerful effect on immune cells, particularly CD4+ T cells. In animal models, SPD was observed to accumulate in the liver following BLE administration, with increased levels of IFN-γ and IL-21—key cytokines in antiviral immunity. The pathway involves SPD-induced autophagy, which enhances the functional capacity of CD4+ T cells, allowing them to maintain a sustained and effective response against HBV.

Mechanistically, SPD induces autophagy by promoting the hypusination of eukaryotic translation initiation factor 5A (eIF5A), a protein necessary for synthesizing autophagy-related factors. This process supports the accumulation of autophagosomes in CD4+ T cells, crucial for cellular immunity. The study’s results showed that blocking autophagy with inhibitors could significantly dampen IFN-γ production, highlighting the central role of autophagy in SPD-mediated immune enhancement.

Impact of Probiotics and SPD in Human and Animal Models

In animal models, probiotics not only enhanced gut microbial diversity but also demonstrated significant reductions in serum HBV DNA and HBsAg levels. Furthermore, germ-free mice treated with BLE exhibited a higher abundance of CD4+ T cells in the liver and spleen, which was associated with increased IFN-γ and IL-21 production.

The promising findings extended to a human study where HBV patients under antiviral treatment received BLE supplementation. Among these patients, BLE supplementation resulted in a notable decline in serum HBsAg levels over six months. Importantly, three patients achieved complete HBsAg clearance—a promising indicator for the potential use of probiotics as a complementary therapy for HBV infection.

Implications and Future Directions

The study by Wang et al. introduces a novel therapeutic angle for chronic HBV management, proposing probiotics and spermidine as adjuncts to conventional therapies. The benefits of this approach include not only enhanced antiviral immunity but also the safe and accessible nature of probiotics, making this strategy feasible for widespread clinical application. The study also opens avenues for investigating SPD and other metabolites in immune regulation, especially in the context of liver diseases influenced by gut-liver interactions.

This research supports the concept that modulating the gut microbiota and harnessing microbial metabolites can strengthen immune defenses and improve viral clearance. Future studies will be necessary to validate these findings in larger patient cohorts and explore the potential of SPD as a standalone therapeutic or in combination with other immune modulators.

Conclusion

Probiotics and their metabolite spermidine represent a promising new strategy for enhancing immune responses against chronic HBV infection. By promoting intestinal health, enhancing CD4+ T cell function, and increasing autophagic activity, these interventions may pave the way for more effective and accessible HBV treatments, moving closer to the goal of a functional cure for this pervasive disease.

For Further Reading

1. Probiotics and their metabolite spermidine enhance IFN-γ+CD4+ T cell immunity to inhibit hepatitis B virus
2. Induction of colonic regulatory T cells by indigenous Clostridium species
3. Microbiota in T-cell homeostasis and inflammatory diseases
4. Regulation of short-chain fatty acids in the immune system
5. The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome
6. Microbiota in T-cell homeostasis and inflammatory diseases
7. Probiotics Can Boost the Antitumor Immunity of CD8+T Cells in BALB/c Mice and Patients with Colorectal Carcinoma
8. Gut Microbiota, Leaky Gut, and Autoimmune Diseases
9. Microbiota-immune interactions: from gut to brain